Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization

Marie-Stéphanie Aschtgen1, Konstantinos Fragkoulis1, Gema Sanz1, Staffan Normark1,2, Galina Selivanova1, Birgitta Henriques-Normark1,2 and Sylvain Peuget1,2

© The Author(s) 2022

Increasing evidence highlights the role of bacteria in the physiopathology of cancer. However, the underlying molecular mechanisms remain poorly understood. Several cancer-associated bacteria have been shown to produce toxins which interfere with the host defense against tumorigenesis. Here, we show that lipopolysaccharides from Klebsiella pneumoniae and other Enterobacteria strongly inhibit the host tumor suppressor p53 pathway through a novel mechanism of p53 regulation. We found that lipopolysaccharides destabilize TP53 mRNA through a TLR4-NF-κB-mediated inhibition of the RNA-binding factor Wig-1. Importantly, we show that K. pneumoniae disables two major tumor barriers, oncogene-induced DNA damage signaling and senescence, by impairing p53 transcriptional activity upon DNA damage and oncogenic stress. Furthermore, we found an inverse correlation between the levels of TLR4 and p53 mutation in colorectal tumors. Hence, our data suggest that the repression of p53 by Enterobacteria via TLR4 alleviates the selection pressure for p53 oncogenic mutations and shapes the genomic evolution of cancer.

Oncogene (2022) 41:2173–2186; https://doi.org/10.1038/s41388-022-02238-5

Over the last decades, the human microbiome has emerged as an important regulator of the physiopathology of cancer and it has been estimated that infections could be the main driver for over 20% of cancers [1]. Recent evidence highlights the role of the bacterial microbiota in cancer initiation, progression and response to therapy [2]. Enrichment of specific bacterial species has been found in cancer patients by metagenomics study, linking bacterial dysbiosis to cancer [3, 4]. Moreover, the ability for oncogenic bacteria to act as cancer drivers and to initiate tumorigenesis has been demonstrated for Helicobacter pylori [5] as well as for genotoxin-producing bacteria [6, 7]. Several other bacterial species have also been experimentally associated to increased cancer risk, such as Fusobacterium nucleatum [8]. Overall, the essential role of the bacterial microbiota in cancer is now well established. However, despite recent advances, the underlying molecular mechanisms by which our microbiota influences cancer remain elusive.

Bacteria produce multiple toxins, metabolites and pro-inflammatory molecules which directly or indirectly target host signaling pathways involved in all the cancer hallmarks and thereby interfere with the host defense against tumorigenesis, such as the p53 pathway. The tumor suppressor p53, encoded by the TP53 gene, is a transcription factor which acts as a cell signaling hub to integrate various cell stresses into an appropriate cell response [9]. Upon stress, phosphorylation events lead to the dissociation of p53 from its ubiquitin-ligase MDM2, preventing its degradation by the proteasome and leading to its accumulation in the nucleus. p53 controls transcription programs regulating multiple cell functions including apoptosis, cell cycle arrest and DNA damage response, and acts as the main barrier against tumorigenesis. Additionally, p53 has been long known to be involved in host defense against viral infection, due to its role in the DNA damage response, and hence it is specifically targeted by oncogenic viruses [10, 11]. Interestingly, known oncogenic bacteria such as H. pylori [12–14], Chlamydia trachomatis [15] and several Mycoplasma species [16] also interfere with the p53 pathway. Altogether, these studies suggest that p53 inactivation could be a more general hallmark of microbes with tumorigenic potential.

Klebsiella pneumoniae is an opportunistic pathogen of the digestive and upper respiratory tract. Metagenomics and clinical epidemiologic data suggest that K. pneumoniae could play a role in cancer initiation and progression. K. pneumoniae has been shown to be enriched in the gut of colorectal cancer patients (CRC) [17]. Moreover, hypervirulent strains of K. pneumoniae, which cause pyogenic liver abscesses, have been associated with increased risk of CRC [18, 19]. Interestingly, several hypervirulent K. pneumoniae strains harbor the pks locus encoding for the genotoxin colibactin which could be involved in K. pneumoniae tumorigenic potential [20]. However, the mechanisms that link K. pneumoniae and cancers are still poorly understood. In this study, we investigate the impact of K. pneumoniae on the host p53 pathway. We find that lipopolysaccharide (LPS) from K. pneumoniae and other Enterobacteria inhibits p53 through the TLR4-NF-κB pathway, and we uncover a novel mechanism of p53 regulation whereby p53 inhibition occurs at the mRNA level.

1Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden. 2Clinical Microbiology, Karolinska University Hospital, 171 76 Stockholm, Sweden. 3Email: marie-stephanie.aschtgen@ki.se; sylvain.peuget@ki.se

Received: 31 August 2021 Revised: 24 January 2022 Accepted: 8 February 2022
Published online: 23 February 2022
RESULTS

Klebsiella pneumoniae inhibits p53

To investigate the effect of K. pneumoniae on the host p53 pathway, we infected human immortalized fibroblasts (BJ hTERT) with live bacteria. We observed a robust downregulation of p53 protein level, concomitant with the activation of NF-κB, as demonstrated by Ser536 phosphorylation of the NF-κB subunit p65 (RelA) (Fig. 1a). Interestingly, p53 downregulation was bacteria-cell contact independent and was recapitulated when treating the cells with supernatant from K. pneumoniae culture (KpSN), independently of the K. pneumoniae strains used (Fig. 1b and Supplementary Fig. S1a-b).}

Pathway analysis of gene expression changes in human fibroblasts exposed to KpSN, measured by RNA-seq, highlighted a robust activation of the canonical immune and inflammatory pathways involved in the host response to bacteria, as expected (Fig. 1c-d). Notably, the analysis of genes downregulated upon KpSN revealed a significant inhibition of the p53 signaling pathway and DNA damage response (Fig. 1d). These data suggest that K. pneumoniae-mediated p53 protein decline is sufficient to impair the biological function of p53.
Core p53 targets 

(Fisher) n=306

Doxorubicin UP

n=3291

shp53 DOWN

n=1716

2161

905

632

161

6364

18

Row Z-score

-1 0 1

p53 target genes (161)

Kp

SN

Dox 0.2 μM

-- +

-+ +

p53

β-ac/g415n

Kp

SN 8h

-- ++

-+ -+

pS536-p65

BJ hTert BJ hTert shp53

-7 0 kDa

-5 5

-4 0

cba
d

f

Rela/g415ve mRNA level (log2Fc)

-1 0 1 2 3 4

Dox

Kp

SN

-- ++

-+-+

shp53

PMAIP1 (NOXA)

Rela/g415ve mRNA level (log2Fc)

-4 -2 0 2 4

Dox

Kp

SN

-- ++

-+-+

shp53

CDKN1A (p21)

Rela/g415ve mRNA level (log2Fc)

-1 0 1 2 3 4

Dox

Kp

SN

-- ++

-+-+

shp53

TP53I3 (PIG3)

Rela/g415ve mRNA level (log2Fc)

-4 -2 0 2 4

Dox

Kp

SN

-- ++

-+-+

shp53

TP53INP1

Rela/g415ve mRNA level (log2Fc)

-4 -2 0 2 4

Dox

Kp

SN

-- ++

-+-+

shp53

SESN1

Rela/g415ve mRNA level (log2Fc)

-6 -4 -2 0 2 4

Dox

Kp

SN

-- ++

-+-+

shp53

ZMAT3 (Wig-1)

Rela/g415ve mRNA level (log2Fc)

-6 -4 -2 0 2 4

Dox

Kp

SN

-- ++

-+-+

shp53

Fig. 2  Klebsiella pneumoniae impairs p53 response to DNA damage. a Western blot of BJ hTert cells treated with the DNA-damaging agent doxorubicin (Dox) and with KpSN. b High confidence set of p53 target genes obtained by intersecting the core p53 target gene set define by Fisher et al. with genes upregulated by doxorubicin and downregulated upon p53 knock-down in our RNA-seq data from BJ hTert cells. c RNA-seq data of high-confidence p53 target genes expression upon doxorubicin and KpSN. d Expression change of selected well-characterized p53 target genes in RNA-seq data of BJ hTert cells exposed to KpSN. e RT-qPCR validation of selected p53 target genes in BJ hTert cells upon exposure to doxorubicin, KpSN and p53 knockdown. f Western blots of BJ hTert cells (wt and p53 knockdown) showing protein level of p53 target genes upon 16 h exposure to doxorubicin and KpSN. *p < 0.05; ***p < 0.01.
Klebsiella pneumoniae impairs the p53 response to DNA damage and oncogenic stress

To confirm that K. pneumoniae-induced downregulation of p53 impacts its transcriptional activity, we investigated the effect of KpSN on p53 level and activity upon doxorubicin-induced DNA damage, which is well known to stabilize p53 and activate its target genes. First, we confirmed that upon DNA damage, the stabilization of p53 is impaired in KpSN treated cells (Fig. 2a). Then, we investigated how it affects p53-dependent transcription. The set of genes regulated by p53 is highly dependent on the cell context [21]. Therefore, we defined a gene set of 161 high confidence p53 targets in our model. We intersected genes upregulated upon DNA damage in a p53-dependent manner in BJ-hTERT fibroblasts (which were not induced by doxorubicin upon p53 shRNA according to our RNA-seq data) with the p53 core targets gene set defined by Fisher et al. [22] (Fig. 2b). Then, we compared how KpSN affected doxorubicin-induced activation of our gene set of 161 high confidence p53 targets. Our analysis revealed an overall inhibition of p53 upon DNA damage (Fig. 2c). Using RT-qPCR, we investigated the expression of well characterized p53 target genes PMAIP1 (NOXA), CDKN1A (p21), TP53I3 (Pig3), SESN1, as well as ZMAT3 (Wig-1) and TP53INP1 which have been recently highlighted as major effectors of p53-mediated tumor suppression [23, 24] (Fig. 2d-e). Interestingly, both PMAIP1 and CDKN1A were upregulated by KpSN in a p53-independent manner. However, KpSN partially prevented a robust p53-mediated induction of CDKN1A upon doxorubicin and strongly impaired the induction of TP53I3, SESN1 and TP53INP1. Notably, while we observed a diminished ZMAT3 induction upon DNA damage, ZMAT3 was repressed by KpSN in a p53-independent manner (Fig. 2e). We then confirmed the KpSN-induced impairment of the p53 response to DNA damage at protein level (Fig. 2f).

To investigate the biological consequences of K. pneumoniae-induced inhibition of p53, we used BJ fibroblasts with an inducible oncogenic Ras system (BJ hTert HRasV12ER-Tam) as a model of oncogenic stress. In these cells, activation of oncogenic Hras by 4-hydroxytamoxifen (4-OHT) induces a strong p53- and p21-dependent senescence [25]. We monitored senescence by increase in β-galactosidase activity (Fig. 3a-b) and by cell replication arrest revealed by EdU incorporation assay (Fig. 3c-d). We found that KpSN impairs p53-dependent induction of senescence upon oncogene activation, as well as prevents accumulation of p53 and p21 (Fig. 3e).

Overall, our data show that secreted factors from K. pneumoniae downregulate p53 protein level upon DNA damage and oncogenic stress, which impairs its transcriptional activity and its tumor suppressive function.

Fig. 3 Klebsiella pneumoniae impairs p53 response to oncogenic stress. Oncogenic Hras was activated for 7 days by 4-OHT in BJ hTert HRasV12ER-Tam inducible fibroblasts to cause replication stress. a Senescence induced by Hras activation was monitored by quantification of β-galactosidase positive cells upon exposure to KpSN or p53 knock-down. b Representative images of β-galactosidase staining. c Senescence-associated replication arrest was assessed by microscopy-based EdU incorporation assay. d Representative fluorescence microscopy images of EdU staining. DAPI was used to counterstain nuclei. e Protein levels of phospho-p65, p53 and p21 after 72 h of RAS induction. *p < 0.05; ***p < 0.01.
Klebsiella pneumoniae lipopolysaccharide (LPS) is sufficient to inhibit p53

We then investigated which K. pneumoniae secreted factor is responsible for host p53 downregulation. We performed a molecular weight fractionation of KpSN and heat treatment (Fig. 4a). The effect on p53 was recapitulated by the heat-resistant fraction of high molecular weight (>100 kDa). This fraction contains bacterial outer membrane vesicles (OMVs) associated with LPS, suggesting that LPS could be the signal for p53 downregulation. Indeed, purified LPS from K. pneumoniae induced a robust downregulation of p53 protein in immortalized fibroblasts in a dose-dependent manner (Fig. 4b). We confirmed this effect in primary human fibroblasts, M1 and M2 monocyte-derived macrophages, and melanoma cell line A375 (Supplementary Fig. S2a). Moreover, addition of polymyxin B to the culture medium, known to block the effects of LPS through binding to

---

**Fig. 4** *Klebsiella pneumoniae* LPS is sufficient to inhibit p53. a Western Blot of BJ hTert cells treated with different KpSN fractions. b Western blot of BJ hTert cells upon exposure to purified K. pneumoniae LPS. c Effect of LPS inactivation by polymyxin B on BJ hTert cells response to LPS or KpSN assessed by Western blot. Culture medium containing purified LPS (100 ng/mL) or KpSN was treated 24 h with 30 μg/mL of polymyxin B sulfate before addition to cells. d Western blot of BJ hTert cells infected by *K. pneumoniae Δlpxm* or exposed to KpSN from Δlpxm bacteria. Lpxm deletion was complemented using a pBAD plasmid expressing lpxM (Δlpxm + lpxm). e TLR4 dependency of BJ hTert cells response to KpSN assessed by Western blot upon treatment with TLR4 inhibitor TAK242. f NF-κB dependency of BJ hTert cells response to KpSN assessed by Western blot using Tet-inducible p65 knock-down BJ hTert cells. p65 shRNA was induced by doxycycline for 48 h before the experiment. g Protein level of phospho-p65 and p53 in BJ hTert cells upon exposure to culture supernatant from different bacteria species. h Negative correlation between TLR4 expression and p53 mutation in early grade colorectal adenocarcinoma patients data (COAD, TCGA) suggests that TLR4-driven inhibition of p53 alleviate the selection pressure for p53 mutation in cancer. i Comparison of p53 mutation rate between early colorectal adenocarcinoma with low and high TLR4 expression.
**Fig. 5**  
**p53 inhibition occurs at mRNA level.**  

- **a** Downregulation of p53 protein level induced by KpSN in BJ hTert cells is not rescued by MDM2 inhibitor Nutlin or by proteasome inhibitor MG132.  
- **b** Proteasome inhibition by MG132 does not rescue p53 downregulation upon direct infection of BJ hTert cells by K. pneumoniae (m.o.i. 10).  
- **c** p53 protein stability in BJ hTert cells exposed to KpSN (orange) or 100 ng/mL LPS (pink) was investigated using cycloheximide (CHX) chase assay. Cells were pretreated 4 h with KpSN before CHX treatment.  
- **d** RT-qPCR for TP53 mRNA level of BJ hTert cells upon 8 h exposure to KpSN, assessed by.  
- **e** RT-qPCR for TP53 mRNA level of BJ hTert cells upon 8 h exposure to indicated dose of LPS.  
- **f** RT-qPCR for TP53 mRNA level upon KpSN or 100 ng/mL LPS (8 h) in PBMC-derived macrophages, polarized into M1 phenotype. The different data point symbols indicate different blood donors.  
- **g** Luciferase reporter assay using TP53 promoter-Luc construct transfected in BJ hTert cells. Transfection rate was normalized by co-transfection of Renilla luciferase vector. Endogenous TP53 mRNA level was measured in the same samples.  
- **h** Luciferase reporter assay using a construct expressing the luciferase flanked by p53 UTRs, transfected in BJ hTert cells. Transfection rate was normalized by co-transfection of Renilla luciferase vector. Endogenous TP53 mRNA level was measured in the same samples.  
- **i** Upper panel: structure of the TP53 gene with the two alternative promoters P1 and P2. Lower panel: mRNA level of P1 and P2 p53 isoforms in BJ hTert cells upon treatment with KpSN or 100 ng/mL LPS (8 h).  

*p < 0.05; ***p < 0.01; NS non-significant.
Fig. 6 LPS-induced downregulation of ZMAT3 destabilizes TP53 mRNA. a Differential expression level of known factors regulating TP53 3'UTR in our RNA-seq data of KpSN-treated BJ hTert cells. b Left panel: Western blot of BJ hTert cells upon 8 h treatment with KpSN and doxorubicin. Right panel: densitometric quantification of Wig-1 and PIG3 Western blot bands normalized to β-actin level. c RT-qPCR for ZMAT3 mRNA level upon KpSN or 100 ng/mL LPS (8 h) in PBMC-derived macrophages, polarized into M1 phenotype. The different data point symbols indicate different blood donors. d Left panel: Western blot of M1 macrophages upon KpSN or LPS treatment. Right panel: densitometric quantification of p53 and Wig-1 Western blot bands normalized to β-actin level. e mRNA level of TP53 and ZMAT3 in RNA-seq data from PBMC-derived macrophages from 60 different blood donors infected by Salmonella typhimurium. f Validation of Wig-1 binding to TP53 mRNA in BJ hTert cells by RIP-qPCR. g Rescue of KpSN-induced p53 downregulation in BJ hTert cells by Wig-1 overexpression but not by the RNA-binding deficient H88A mutant, assessed by RT-qPCR. h Left panel: Western blot of Wig-1 and Wig-1*H88A overexpressing BJ hTert cells upon KpSN treatment. Right panels: densitometric quantification of p53 and Wig-1 Western blot bands normalized to β-actin level. *p < 0.05; ***p < 0.01; NS non-significant.
lipid A, completely rescued the downregulation of host p53 (Fig. 4c). To confirm the involvement of lipid A, we generated a K. pneumoniae deletion mutant for the lipM gene, which encodes a myristoyl transferase that catalyzes the final step of lipid A biosynthesis (Supplementary Fig. S2b). Deletion of lipM did not affect bacterial growth nor the amount of LPS secreted (Supplementary Fig. S2c, d). However, K. pneumoniae ΔlipM was unable to affect p53 protein level in host cells, neither upon direct infection nor upon treatment with bacterial supernatant, while the complemented strain restored the downregulation (Fig. 4d). Altogether, these results demonstrate that K. pneumoniae inhibits p53 through the lipid A of its LPS.

To further examine which host pathway is involved, we performed similar experiments while inhibiting the classical LPS signaling pathway, including its receptor TLR4 or the major cellular mediator NF-κB. Both TLR4 inhibitor and Tet-inducible knockdown of the NF-κB subunit p65 completely rescued the inhibition of host p53 (Fig. 4e, f). As the TLR4-NF-κB axis is a canonical signal transduction pathway activated by LPS from most Gram-negative bacteria, we investigated if the effect on p53 is shared with other bacterial species (Fig. 4g and Supplementary Fig. S2e). Indeed, culture supernatants from other Enterobacteria (Salmonella typhimurium, Shigella flexneri, Escherichia coli) also strongly repressed p53. In contrast, p53 was activated by Gram-positive Streptococcus pneumoniae. Importantly, we did not observe p53 repression by LPS from commensal Gram-negative Bacteroides fragilis, which is known to have a penta-acetylated lipid A structure acting as TLR4 antagonist [26]. However, p65 was phosphorylated to a similar extent, suggesting that besides the canonical NF-κB pathway, other transduction pathways are involved in p53 repression.

Next, we explored if the inhibition of p53 by LPS/TLR4 could play a role in tumor initiation or progression, using data from cancer patients deposited in the Cancer Genome Atlas (TCGA). We hypothesized that inhibition of p53 by bacterial signaling could alleviate the selection pressure for p53 mutation in TLR4 expressing tumors. Hence, we investigated the relationship between the TLR4 expression level and the p53 mutation rate in early-stage colorectal adenocarcinoma (grade I-II). We observed a robust correlation ($p < 0.0001$) between TLR4 mRNA level and absence of a p53 mutation in the tumors (Fig. 4h). Moreover, comparison between tumors with high TLR4 (Z-score > 0.75) and low TLR4 (Z-score < -0.75) revealed a striking inversion of the p53 mutation rate (Fig. 4i). While these data could be explained by a transcriptional control of TLR4 by wild-type p53, as previously suggested by Menendez et al. [27], we did not observe the same correlation in other tumor contexts known to have no or low bacterial load (such as breast and liver cancers) or with a lower abundance of Gram-negative bacteria (such as lung cancer) [28] (Supplementary Fig. S3a, b). These data suggest that activation of the TLR4-NF-κB by LPS from the microbiota could contribute to tumorigenesis by restricting p53 tumor suppressive function and shed a new light on the known pro-tumorigenic effect of LPS [29].

p53 inhibition occurs at the mRNA level

p53 has been extensively described to be regulated solely at the protein level, through modification of its stability, conformation and/or protein interactions [9]. To ensure a fast response to stress, p53 is constantly produced and targeted to protein degradation through MDM2-dependent polyubiquitination. Several bacterial toxins have been described to enhance p53 degradation through AKT-mediated activation of MDM2 [30]. Calpain-cleavage of p53 by bacteria has also been reported [31]. Surprisingly, we found that downregulation of p53 by KpSN did not involve enhanced proteasomal degradation. While p53 was indeed stabilized upon proteasome inhibition by MG132 or MDM2 inhibition by Nutlin, we did not observe any prevention of the p53 decline induced by KpSN or by K. pneumoniae direct infections (Fig. 5a-b). Similarly, doxorubicin-induced DNA damage (which leads to disruption of the p53-MDM2 complex and p53 stabilization) did not rescue KpSN-induced p53 downregulation (Fig. 2a). Inhibition of AKT or calpain also both failed to rescue p53 protein level (Supplementary Fig. S4a). Moreover, analysis of p53 protein stability by cycloheximide chase assay did not reveal any significant change in p53 stability when cells were exposed to KpSN or LPS (Fig. 5c).

Since our data showed that p53 protein stability was not affected, we investigated the TP53 mRNA by RT-qPCR and found that KpSN strongly decreased TP53 mRNA level in human immortalized fibroblasts (BJ hTert) (Fig. 5d-e), normal primary fibroblasts (HNF) and in A375 melanoma cells (Supplementary Fig. S4b-c). This effect was recapitulated in a dose-dependent manner upon treatment of cells with K. pneumoniae LPS (Fig. 5e and Supplementary Fig. S4d). We also observed the repression of TP53 mRNA level in M1 and M2 monocytes-derived macrophages upon treatment with KpSN or LPS (Fig. 5f and Supplementary Fig. S4e).

Finally, inhibition of TLR4 or deletion of K. pneumoniae lipM prevented TP53 mRNA downregulation (Supplementary Fig. S4f, g).

TP53 gene transcription has previously been described to be repressed by phosphorylated STAT3 upon LPS [32]. However, we did not observe a rescue of TP53 mRNA in STAT3-depleted cells (Supplementary Fig. S4h-i). Taken together, our results suggest a novel mechanism of p53 regulation by LPS-TLR4-NF-κB through STAT3-independent regulation of TP53 mRNA.

To identify the mechanism of TP53 mRNA inhibition by K. pneumoniae, we tested whether TP53 mRNA expression was affected at the promoter level or post-transcriptionally through TP53 mRNA UTRs. We performed dual luciferase reporter assays using a construct where the luciferase expression is under the control of the TP53 promoter (TP53 promoter-Luc) and another construct constitutively expressing the luciferase mRNA flanked by TP53 untranslated regions (Luc-TP53 UTRs). Inhibition of endogenous TP53 was controlled in the same sample by RT-qPCR. We did not observe any change in luciferase expression of TP53 promoter-Luc upon treatment with KpSN or LPS (Fig. 5g), suggesting that the promoter activity of TP53 is not affected. However, both KpSN and LPS induced a robust decrease in luciferase from the Luc TP53 UTRs plasmid (Fig. 5h), indicating that KpSN and LPS might regulate TP53 mRNA stability through its UTRs. To find out which UTR was involved, we investigated the regulation of different p53 isoforms (Fig. 5i). TP53 gene encodes two families of p53 isoforms through an alternative promoter P2 located in intron 4, which regulates the expression of short isoforms (Δ133 and Δ160 p53 isoforms), while the full length isoforms are regulated by its main promoter P1 [33]. P1 and P2 isoforms share their 3'-UTR but have different 5'-UTR sequence and different promoter regulation. Using RT-qPCR with isoform-specific primers, we found that both isoform families are similarly repressed by KpSN and LPS, suggesting a regulation of the TP53 3'-UTR (Fig. 5i).

LPS-induced downregulation of ZMAT3 destabilizes TP53 mRNA

We then investigated the expression of genes known to regulate TP53 mRNA by binding its 3'UTR [34]. Interestingly, we observed that several genes encoding factors stabilizing TP53 mRNA (such as ZMAT3 or CPEB1) [35, 36] were repressed upon exposure to KpSN, while factors known to inhibit its translation (such as Tia1) [37] where activated. Strikingly, ZMAT3, which encodes the RNA binding protein Wig-1, was one of the top repressed genes in our RNA-seq data (Fig. 1c). Wig-1 has been shown to bind to an A/U-rich element (ARE) on TP53 3'UTR to stabilize TP53 mRNA [35]. Moreover, ZMAT3 forms a regulatory feedback loop with p53 since it is a p53 target gene crucial for p53 tumor suppression [23, 24]. As we already showed that ZMAT3 repression upon KpSN is p53 independent (Fig. 2e), we tested if...
Wig-1 was inhibited at earlier time points (8 h) than other p53 targets. We observed the downregulation of both isoforms of Wig-1 at the same time frame as TP53 mRNA but before other p53 targets such as PIG3 (Fig. 6b and Fig. 2f). Moreover, Wig-1 was repressed at mRNA and protein level in M1 and M2 monocytes-derived macrophages (Fig. 6c, d and Supplementary Fig. S5a-b). Analysis of RNA-seq data from PBMC-derived macrophages from 60 different blood donors infected by *Salmonella* *typhimurium* [38] confirmed the robust inhibition of both TP53 and ZMAT3 upon direct infection of macrophages by another Enterobacterial species (Fig. S6).

To confirm the role of Wig-1 in p53 downregulation, we validated the binding of Wig-1 to TP53 mRNA by RIP-qPCR in our model (Fig. 6f). Then, we established fibroblasts stably overexpressing wild type Wig-1 (BJ hTert pLV Wig-1) or a zinc-finger mutant unable to bind TP53 mRNA [35] (BJ hTert pLV Wig-1*H88A). Overexpression of wt Wig-1, but not of the H88A mutant, partially rescued both TP53 mRNA and p53 protein levels (Fig. 6g-h), demonstrating that repression of ZMAT3 gene by KpsN participates in the destabilization of TP53 mRNA. Finally, ZMAT3 repression also affected the stability of several other mRNAs, previously described to be either stabilized (such as *Elf4B* and *Rrm1*) [39] or destabilized by Wig-1 (such as *Fas*) [40], suggesting a broader effect than p53 inhibition (Supplementary Fig. S5c, d). We then investigated the mechanism of ZMAT3 repression. We found that knock-down of p65 rescued Wig-1 downregulation, confirming the NF-kB involvement in ZMAT3 repression by KpsN (Fig. 7a). LPS-induced repression of genes through NF-kB has been recently shown to be regulated by histone deacetylases (HDACs) [41]. Using two different pan-HDACs inhibitors, vorinostat and belinostat, we could rescue the downregulation of ZMAT3 mRNA upon KpsN as well as Wig-1 and p53 proteins (Fig. 7b, c), confirming HDACs-dependent repression of ZMAT3. Altogether, our results demonstrate that activation of the TLR4-NF-kB pathway by bacterial LPS leads to destabilization of TP53 mRNA through its 3’ UTR, mediated by inhibition of RNA-stabilizing factors such as Wig-1.

In conclusion, our data reveal a novel mechanism of p53 inhibition during the cell response to *K. pneumoniae* and other Enterobacteria, through NF-kB-dependent destabilization of TP53 mRNA, p53 protein downregulation and impairment of its transcriptional activity and tumor suppressive function.

**DISCUSSION**

In this study, we discovered that *K. pneumoniae* strongly inhibit p53 and prevent its anti-tumorigenic functions. Interestingly, we found that *K. pneumoniae* LPS was sufficient to inhibit p53. Moreover, our data point out to a more general mechanism of TP53 mRNA repression by TLR4 agonist LPS from Enterobacteria, which elicits the canonical LPS-TLR4-NF-kB pathway. Our results shed a new perspective on published data about p53 response to bacteria, where inhibition of p53 downstream of microbe-associated molecular patterns (MAMPs) and pattern recognition receptors (PRRs) signaling has not been investigated [15, 42].

The mechanisms controlling p53 protein stability have been extensively characterized and accepted as the major level of p53 regulation [43]. Only few studies addressed the regulation of TP53 mRNA during the host response to stress [44–46]. Our findings reveal that TP53 mRNA serves as an important regulatory platform to turn off p53 activity upon infection and NF-kB activation. The NF-kB and p53 pathways have long been known to be tightly intertwined and to antagonize each other at multiple levels [47, 48]. p53 activation impairs NF-kB function, including in response to LPS [49, 50], and conversely, loss of p53 increases NF-kB activity [51]. Therefore, p53 inhibition in innate immune cells and fibroblasts exposed to MAMPs could be crucial to ensure a proper NF-kB-dependent inflammation and innate immune response. Supporting this hypothesis, p53 KO mice infected by *K. pneumoniae* display an enhanced bacterial clearance by neutrophils and macrophages [52]. Additionally, post-transcriptional mRNA processing have recently emerged as a...
TLR4 expression and p53 mutation rate in CRC. Our results support cancer patient data demonstrated an inverse correlation between Upon LPS signaling (right panel), activation of the canonical TLR4-NF-κB pathway inhibits ZMAT3 transcription via HDACs, preventing TP53 mRNA stabilization and ultimately impairing p53 tumor suppressive function. Additionally, p53 is unable to inhibit NF-κB, allowing a robust inflammatory response.

Fig. 8 Schematic representation of p53 inhibition by LPS. Upon oncogenic or genotoxic stress (left panel), p53 is stabilized, and induces ZMAT3/Wig-1 expression. In turn, Wig-1 stabilizes TP53 mRNA, leading to a robust p53 accumulation, p53 activity and tumor suppression. Upon LPS signaling (right panel), activation of the canonical TLR4-NF-κB pathway inhibits ZMAT3 transcription via HDACs, preventing TP53 mRNA stabilization and ultimately impairing p53 tumor suppressive function. Additionally, p53 is unable to inhibit NF-κB, allowing a robust inflammatory response.

key level of regulation to coordinate the switch from immune cell proliferation to activation during innate immune response [38]. Our finding that RNA binding factors such as Wig-1 are among the top differentially expressed genes is consistent with this idea. Importantly, Wig-1 forms a positive feedback loop with p53 and it is an important p53 target gene [23, 24]. Thus, our data suggest that TP53 mRNA destabilization and Wig-1 downregulation cooperate during acute inflammation to robustly activate NF-κB to fight bacterial infection, simultaneously weakening tumor barrier (Fig. 8).

Importantly, CRC patients have elevated circulating LPS and systemic inflammation [53]. Moreover, CRC-associated dysbiosis is usually enriched in Gram-negative bacteria [54], which suggests that LPS secretion is an important factor linking bacterial dysbiosis and tumorigenesis. We found that commensal bacteria expressing a TLR4 antagonist LPS, such as B. fragilis, do not downregulate p53, which could contribute to their protective role in colitis-associated colorectal cancer [55]. In addition, colonization of the gut by Enterococcus faecalis, a Gram-positive bacterium, induces inflammatory response and colitis similarly to Enterobacteria colonization but does not induce tumorigenesis [56]. Altogether, it suggests that activation of the TLR4-mediated signaling by LPS plays a critical role in promoting cancer not only by inducing inflammation but also by inhibiting p53.

Chronic inflammation linked to bacterial dysbiosis could cause persistent impairment of p53 tumor suppressor function in innate immune cells, which might create a cellular context favorable for oncogenesis. Supporting this idea, mouse models with genetic inactivation of p53 specifically in myeloid cells are more prone to tumorigenesis [57]. Additionally, inactivation of p53 in the tumor microenvironment have profound consequences on the tumor cells themselves in a non-cell autonomous fashion [58, 59]. As tumor progression is associated with disruption of the epithelial layer and invasion of the tumor by bacteria, MAMPs signaling and downstream inhibition of p53 in cancer-associated fibroblasts and tumor-associated macrophages could fuel tumor development. Accordingly, several studies have shown that LPS activation of TLR4 accelerates tumor growth [29, 60]. Interestingly, our analysis of cancer patient data demonstrated an inverse correlation between TLR4 expression and p53 mutation rate in CRC. Our results support the idea that TLR4 activation disables p53 function in the absence of mutation. Moreover, it suggests that the cancer-associated bacterial microbiota exerts a selection pressure on cancer cells and drives tumor evolution. In line with this hypothesis, recent metagenomics analysis of lung cancer microbiota have shown significant differences in bacterial populations associated with p53 wild-type versus p53-mutant tumors [61]. Further analyses of metagenomics data from cancer patients in connection with tumor genome profiling are required to understand the connection between the microbiota and host genomic alterations.

METHODS
Bacterial strains
All bacterial strains used in this study are listed in Supplementary Table S1. K. pneumoniae SHG4 and SHG10 strains were a gift from Y.-H. Gan [62, 63], IA565 strain was a gift from G. Huffnagle [64]. Enterobacteria were grown either in DMEM 10% FBS, Luria Broth or low salt Luria Broth at 37 °C. S. pneumoniae was grown on agar blood plates at 37 °C with 5% CO2. B. fragilis was grown on agar blood plates at 37 °C under anaerobic conditions. When stated, 100 μg/mL gentamycin, 50 μg/mL hygromycin, 50 μg/mL apramycin was added to the culture.

K. pneumoniae lpxM deletion mutant (ΔlpxM) was constructed using a previously established allelic exchange method with a few modifications [65]. Briefly, the apramycin resistance cassette with extensions homologous to regions adjacent to lpxM was generated by PCR using the plu773 plasmid [65] as a template (primers: forward 5′-CTACACTATCCCCATTATCTTGATTA GCACTGATCTCTCGGATTTGCGATTGCGATGCAGC-3′; reverse 5′- CGAGAAAGCGAAGGATAGAAAAAGCTCCTCGGAGGCTTGTGTAGT AGGCAGAAGTCTGCTC-3′). The PCR product was then electroporated into K. pneumoniae cells carrying the pSIM18 plasmid [66]. Replacement of the gene by the apramycin resistance cassette flanked by two Flp recombinase target sequences was confirmed by PCR. The resulting strain was then transformed with the pFLP-hyg plasmid (Addgene #87831; [65]) and incubated for 24 h at 30 °C, allowing excision of the cassette by the Flp recombinase. Plasmid pFLP-hyg was then eliminated at 42 °C, and the cassette excision was verified by sequencing. The pBAD33-gent plasmid producing lpxM was constructed by standard restriction/ligation cloning by inserting an XbaI-lpxM-HindIII fragment (obtained by PCR using the primers: forward 5′-GATCCTACTAGAGATTGGGCTGAAACGAGCTTCTGGGAGGCT-3′; reverse 5′-GATCAGGCTTCTATCTATTTGGTGATGCAGCGAAGGCTTGTGTAGT AGGCAGAAGTCTGCTC-3′) into the XbaI-HindIII digested pBAD33-gent plasmid (Addgene #65098; [67]).
Human cell lines and primary cells

Human immortalized fibroblasts BJ hTert, BJ hTert shp53, BJ hTert HRasV12ER-Tam and BJ hTert HRasV12ER-Tam shp53 cells were obtained from R. Agami [68]. Human melanoma cell line A375 was from ATCC. Primary human normal fibroblasts (HFN) from dermal biopsies were obtained from A. Falk (Karolinska Institute). Cell authentication was performed by STR profiling analysis at Eurofin Genomics. Mycoplasma contamination was tested monthly using MycoAlert Mycoplasma Detection Kit (Lonza) according to the manufacturer’s instructions. All experiments were performed within 10 passages from frozen stocks.

BJ hTert cells with stable STAT3 knock-down (BJ hTert shSTAT3), inducible p65 knock-down (BJ hTert shp53 shp53-1), or ZMAT3 overexpression (BJ hTert HRasV12ER-Tam) were induced by 3 µg/mL of doxycycline (Sigma-Aldrich) for 48 h. For experiments on PBMC-derived macrophages, monocytes were isolated from anonymous buffy coats of healthy blood donors (Karolinska University Hospital) using Ficoll gradient and centrifugation. Briefly, blood was diluted in PBS and layered on to Ficoll-Paque (GE Healthcare) and centrifuged at 1,200 rpm for 20 min. The interface layer containing the monocytes was collected and further washed twice in PBS. Monocytes were then incubated 2 h for adhesion and unattached cells were washed with PBS. For differentiation into M1 and M2 polarized macrophages, monocytes were cultured in RPMI 1640, 2 mM L-glutamine, 10% FBS, 1% penicillin/streptomycin for 6 days and incubated with 5% Co2 or under anaerobic conditions. Supernatant was collected 24 h before treatment.

For experiments on PBMC-derived macrophages, monocytes were isolated from anonymous buffy coats of healthy blood donors (Karolinska University Hospital) using Ficoll gradient and centrifugation. Briefly, blood was diluted in PBS and layered on to Ficoll-Paque (GE Healthcare) and centrifuged at 1,200 rpm for 20 min. The interface layer containing the monocytes was collected and further washed twice in PBS. Monocytes were then incubated 2 h for adhesion and unattached cells were washed with PBS. For differentiation into M1 and M2 polarized macrophages, monocytes were cultured in RPMI 1640, 2 mM L-glutamine, 10% FBS, streptomycin/penicillin (Sigma-Aldrich) supplemented with increasing concentration of Granulocyte-Macrophage Colony-Stimulating Factor (Sigma; up to 400 ng/ml) or Macrophage Colony-Stimulating Factor human (Sigma-Aldrich; up to 40 ng/ml) for 7 days.

Transient infections of BJ hTert cells and bacteria cell free supernatant preparation

For transient bacterial infections, overnight DMEM cultures of S. pneumoniae or R. agama were diluted in fresh medium (DMEM, 10% FBS) and 2 x 10^5 BJ hTert cells seeded in 6-wells plate were infected with a multiplicity of infection (m.o.i.) of 0.1 to 10 as indicated. After 2 h, cells were washed 3–6 times and incubated in cell culture medium with 200 µg/mL gentamicin for an extra 6 h.

Luciferase reporter assay

Transient infections of BJ hTert cells and bacteria cell free supernatant preparation were serially diluted in pyrogen-free water and reagents. The luciferase reporter assay was performed as described previously [70]. Luciferase activity was measured using the Pierce LAL chromogenic endotoxin quantification kit (LifeTechnologies), according to the manufacturer’s instructions but halving the suggested volumes. Luciferase reporter assays were performed by counting positive cells in n ≥ 3 independent experiments.

Measurement of oncoregulated induction of senescence

Cell treatments

Unless stated otherwise, KpSN and other bacterial supernatants were used to supplement culture medium to a final concentration of 10% v/v for 8 h (for RT-qPCR) or 10 h (for Western blots). Purified K. pneumoniae LPS (Sigma-Aldrich) was used at 100 ng/ml for the same duration. Doxorubicin (Sigma-Aldrich) was used at 0.2 µM. For treatments with TAK242, Nutlin, MG132, AKT1/2 kinase inhibitor, calpain inhibitor III, vinostatin (Sigma-Aldrich) and belinostat (WXR), cells were pretreated 2 h with the inhibitor before treatment with KpSN or LPS. For treatment with polymyxin B, medium containing KpSN or LPS was incubated 24 h at 37 °C with 30 µg/ml polymyxin B sulfate (Sigma-Aldrich) before addition to the cells. For cycloheximide chase assay, cells were pre-treated 4 h with KpSN or LPS, and then treated with 10 µM cycloheximide (Sigma-Aldrich) for the indicated time.
sequenced on an Illumina NextSeq 500 system using 2 × 150 bp read length. Quality control was performed using FastQC. rfc-core/maseq pipeline (v1.4) was used to process the reads [71]. HISAT2 (v2.1.0) was used to align the raw RNA-seq fastq reads to the human reference genome (GRCh38.97). Read quantification was computed using featureCounts (v1.6.4). Differential analysis was performed with the R package DESeq2. False positive discovery (FDR) correction and p53 tumor set assessment for differentially expressed genes (DEGs), DEGs were plotted using R package ggplot2. Gene ontology (GO: biological process) and pathway enrichment analysis was performed using gProfiler [72] and visualized using Cytoscape (v3.6.1) [73] as described by Reimand et al. [74]. The complete lists of differentially expressed genes and enriched GO terms upon KpsN treatment are provided in Supplementary Table S3. To define a high confidence gene set of p53 targets in BJ Tert cells, we intersected genes upregulated upon doxorubicin treatment, repressed upon p53 shRNA and p53 core targets genes defined by Fisher et al. [22]. Complete list of the 161 high confidence p53 target genes is provided in Supplementary Table S4.

Public database patient data analysis

Patient data from The Cancer Genome Atlas (TCGA; https://www.cancer.gov/tcga) were analyzed using cBioPortal for Cancer Genomics (http://cbioportal.org) [75, 76]. Normalized expression data and TP53 mutations from early stage (grade I-II) Colorectal adenocarcinoma (COAD), Breast carcinoma (BRCA), Liver hepatocellular carcinoma (LIHC) and Lung adenocarcinoma (LUAD) from TCGA PanCancer Atlas Studies were analyzed. Tumors were classified based on 7LR4 expression Z-score across all samples as high 7LR4 (Z-score > 0.75) or low 7LR4 (Z-score < −0.75).

Statistical analyses

Unless otherwise stated, statistical significance was calculated using two-tailed Student t-test from at least three independent experiments.

DATA AVAILABILITY

The datasets generated in the study are available in GEO database (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE174531.

REFERENCES

1. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
2. Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371.
3. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. The microbiome and human cancer. Science. 2021;371.
4. Mei Q-X, Huang C-L, Luo S-Z, Zhang X-M, Zeng Y, Lu Y-Y. Characterization of the duodenal bacterial microbiota in patients with pancreatic head cancer vs. healthy controls. Pancreatology. 2018;18:438–45.
5. Watabane T, Tada M, Nagai H, Sasaki M, Nakao M. Helicobacter pylori pylori infection induces gastric cancer in mongolian gorbuls. Gastroenterology. 1998;115:842–8.
6. Ge Z, Rogers AB, Fung Y, Lee A, Xu S, Taylor NS, et al. Bacterial cytolytic dis- tending toxin promotes the development of dysplasia in a model of microbially induced hepatocarcinogenesis. Cell Microbiol. 2007;9:2070–80.
7. Cuevas-Ramos G, Petit CR, Marçq I, Bourn Y, Oswald E, Nouyagüe-Jérôme P. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA. 2010;107:11537–42.
8. Brennan CA, Garrett WS. Fusobacterium nucleatum – symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17:156–66.
9. Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that reg- ulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20:199–210.
10. Rivas C, Aaronson SA, Munoz-Fontela C. Dual Role of p53 in Innate Antiviral Immunity. Viruses. 2010;2:298–313.
11. Tomesello ML, Annunziata C, Tomesello AL, Buonaguro L, Buonaguro FM. Human oncoviruses and p53 tumour suppressor pathway deregulation at the origin of human cancers. Cancers. 2018;10:18.
12. Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, et al. Regulation of p53 tumour suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology. 2010;139:1333–43.
13. Harvat A, Noto JM, Ramatchadrin B, Zaika E, Palaisu M, Wei J, et al. Helicobacter pylori pathogen regulates p14ARF tumor suppressor and autophagy in gastric epithelial cells. Oncogene. 2018;37:5054–65.
14. Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helico- bacter pylori cytotoxic-associated gene A (Caga) subverts the apoptosis- stimulating protein of p53 (ASP2P) tumor suppressor pathway of the host. Proc Natl Acad Sci USA. 2011;108:9238–43.
15. González E, Rother M, Kerr MC, Al-Deer MA, Abu-Lubad M, Kessler M, et al. Chlamydia infection depends on a functional MDM2-p53 axis. Nat Commun. 2014;5:3201.
16. Zella D, Curreli S, Benedetti F, Krishnan S, Cocchi F, Latinovic OS, et al. Myco- plasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proc Natl Acad Sci USA. 2018;115:E12005–E12014.
17. Wang T, Cai G, Gu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microflora between colorectal cancer patients and healthy volunteers. ISME J. 2012;6:320–9.
18. Huang W-K, Chang JW-C, Seo L-H, Chen J-S, Liaw C-C, FPW C, et al. Higher rate of colorectal cancer among patients with pyogenic liver abscess with Klebsiella pneumoniae than those without: an 11-year follow-up study. Colorectal Dis. 2012;14:e794–801.
19. Jeong SW, Jang JY, Lee TH, Kim HG, Hong SW, Park SH, et al. Cryptogenic pyo- genic liver abscess as the herald of colon cancer. J Gastroenterol Hepatol. 2012;27:428–55.
20. Lan Y, Zhou M, Jian Z, Yan Q, Wang S, Liu W. Prevalence of pks gene cluster and characteristics of Klebsiella pneumoniae-induced bloodstream infections. J Clin Lab Anal. 2019;33:e22838.
21. Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062–78.
22. Fischer M, Grossmann P, Padl M, DeCaprio JA. Integration of TP53, DREAM, MMB- FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res. 2016;44:6070–80.
23. Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Millia L, Wilcox S, et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat Med. 2018;24:547–53.
24. Bieger-Rolett KT, Kaiser AM, Morgens DW, Bottelle AM, Seoane JA, Van Nostrand EL, et al. Zmn3 is a key splicing regulator in the p53 tumor suppressor pathway. Mol Cell. 2020;80:452–69.e9.
25. Ferbevre de, Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol. 2002;22:3497–508.
26. Berezow AB, Ernst RK, Coats SR, Braham PH, Karimi-Naser LM, Darveau RP. The structurally similar, penta-acylated lipopolysaccharides of Porphyromonas gingivalis and Bacteroides elicits strikingly different innate immune responses. Micro Pathog. 2009;47:68–77.
27. Menendez D, Shatz M, Azzam K, Garantziotis S, Fessler MB, Resnick MA. The toll-like receptor gene family is integrated into human DNA damage and p53 network works. PLoS One. 2010;5:e8578.
28. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PloS One. 2010;5:e9878.
29. Daipto DH, Mencin A, Gwak G-Y, Pradere J-P, Jang M-K, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.
30. Siegel C, Rudel T. Modulation of p53 during bacterial infections. Nat Rev Microbiol. 2015;13:741–8.
31. Bergounioux J, Elisee R, Prunier A-L, Donnadieu F, Sansonetti P, et al. Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium’s epithelial niche. Cell Host Microbe. 2012;11:240–52.
32. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Iby R, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005;25:7432–40.
33. Jorruiz SM, Bourdon J-C. p53 isoforms: key regulators of the cell fate decision. Cold Spr Harb Perspect Med. 2016;6.
39. Bersani C, Huss M, Giacomello S, Xu L-D, Bianchi J, Eriksson S, et al. Genome-wide identification of Wg-1 mRNA targets by RIP-seq analysis. Oncotarget. 2016;7:1895–911.

40. Bersani C, Xu L-D, Vilborg A, Lui W-O, Wiman KG. Wg-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3a. Oncogene. 2014;33:4407–17.

41. Nguyen KCB, Adlammerini M, Hauck AK, Lazar MA. Dichotomous engagement of HDAC3 activity governs inflammatory responses. Nature. 2020;584:286–90.

42. Costa L, Corre S, Michel V, Le Michel, K. Fernandes J, Ziveri J, et al. USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis. Gut. 2020;69:1582–91.

43. Levine AJ, p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471–80.

44. Fu L, Minden MD, Benchimol S. Translational regulation of human p53 gene expression. EMBO J. 1996;15:4392–401.

45. Chen J, Kastan MB. p53 Integrates host defense and cell fate during bacterial pneumonia. J Exp Med. 2013;210:891.

46. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivaress-Illana V, et al. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Genes Dev. 2010;24:2146–56.

47. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivaress-Illana V, et al. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Genes Dev. 2010;24:2146–56.

48. Ak P, Levine AJ. p53 and NF-kB: different strategies for responding to stress lead to a functional antagonism. FASEB J. 2010;24:3643–52.

49. Gudkov AV, Komarova EA p53 and the carcinogenicity of chronic inflammation. Cold Spring Harb Perspect Med. 2016;6.

50. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009;462:104–7.

51. Liu G, Park Y-J, Tsuruta Y, Lorne A, Abraham E. p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury. J Immunol. 2009;182:5063–71.

52. Madenspacher JH, Azzam KM, Gowdy KM, Malcolm KC, Nick JA, Dixon D, et al. Requirement for NF-kappaB and NOTCH in the adaptive response to Helicobacter pylori infection. Cell. 2012;148:1063–75.

53. Komarova EA, Krivokrysenko VW, Wang K, Neznanov N, Chernov MV, Komarov PG, et al. p53 is a suppressor of inflammatory response in mice. FASEB J. 2005;19:1030–2.

54. Madenspacher JH, Azzam KM, Gowdy KM, Malcolm KC, Nick JA, Dixon D, et al. Requirement for NF-kappaB and NOTCH in the adaptive response to Helicobacter pylori infection. Cell. 2012;148:1063–75.

55. He X-Y, Xiang C, Zhang C-X, Xie Y-Y, Chen L, Zhang G-X, et al. p53 in the myeloid lineage modulates an inflammatory microenvironment limiting invasion and expansion of intestinal tumors. Cell Rep. 2015;13:888–97.

56. Procopio M-G, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo S-H, et al. Com- plex cancer genomics of hypervirulent Klebsiella pneumoniae clonal-group 23 reveals early emergence and rapid global dissemination. Nat Commun. 2018;9:2703.

57. Lee IR, Molton JS, Wyres KL, Gorrie C, Wong J, Hoh CH, et al. Pathway enrichment analysis and visualization of omics data using gProfiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc. 2019;14:482–517.

58. Cerami E, Gao J, Drogoszus U, Gross B, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disc. 2012;2:401–4.

59. Gao J, Aksoy BA, Drogoszus U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.

60. Madenspacher JH, Azzam KM, Gowdy KM, Malcolm KC, Nick JA, Dixon D, et al. Requirement for NF-kappaB and NOTCH in the adaptive response to Helicobacter pylori infection. Cell. 2012;148:1063–75.

61. Madenspacher JH, Azzam KM, Gowdy KM, Malcolm KC, Nick JA, Dixon D, et al. Requirement for NF-kappaB and NOTCH in the adaptive response to Helicobacter pylori infection. Cell. 2012;148:1063–75.

62. Lam MMC, Wyres KL, Duchêne S, Wick RR, Judd LM, Gan Y-H, et al. Population genomics of hypervirulent Klebsiella pneumoniae clonal-group 23 reveals early emergence and rapid global dissemination. Nat Commun. 2018;9:2703.

63. Lee IR, Molton JS, Wyres KL, Gorrie C, Wong J, Hoh CH, et al. Pathway enrichment analysis and visualization of omics data using gProfiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc. 2019;14:482–517.

64. Cerami E, Gao J, Drogoszus U, Gross B, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disc. 2012;2:401–4.

65. Gao J, Aksoy BA, Drogoszus U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.

ACKNOWLEDGEMENTS

We thank all our colleagues for sharing precious reagents and material with us, especially Dr. Yunn-Hwen Gan (National University of Singapore), Dr. Gary Huffnagle (University of Michigan) and Mr. Alexandros Petropoulos (Karolinska Institute) for bacteria strains, and Prof. Klas Wiman (Karolinska Institute) for Wig-1 antibody. We thank Ms. Aleksandra Boikova and Mr. Riccardo Bevilacqua for technical support. This study was supported by the Swedish Research Council, the Swedish Cancer Society, Knut and Alice Wallenberg Foundation, the Swedish foundation for Strategic Research and the Karolinska Institute. MSA was supported by a short-term fellowship from EMBO.

AUTHOR CONTRIBUTIONS

MSA and SP designed the study; MSA, KP and SP performed the experiments; MSA, GSz and SP analyzed and interpreted the data; MSA and SP generated the manuscript with the help of GSz, GS, SN and BHN reviewed and edited the manuscript and provided funding.

FUNDING

Open access funding provided by Karolinska Institute.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41388-022-02238-5.

Correspondence and requests for materials should be addressed to Marie-Stéphanie Aschtgen or Sylvain Peuget.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
